Search Result
Results for "
cell fusion
" in MedChemExpress (MCE) Product Catalog:
7
Biochemical Assay Reagents
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P10517A
-
|
SFT acetate
|
HIV
|
Infection
|
|
Sifuvirtide (SFT) acetate is a potent HIV fusion inhibitor. Sifuvirtide acetate inhibits HIV-1 mediated cell fusion in a dose-dependent manner and is highly potent against infection by primary and laboratory-adapted HIV-1 isolates of multiple genotypes. Sifuvirtide acetate can be used in the research of anti-HIV drugs .
|
-
-
- HY-131042
-
|
|
Amine N-methyltransferase
|
Metabolic Disease
|
|
NNMTi is a potent nicotinamide N-methyltransferase (NNMT) inhibitor (IC50=1.2 μM) and selectively binds to the NNMT substrate-binding site residues . NNMTi promotes myoblast differentiation in vitro and enhances fusion and regenerative capacity of muscle stem cells (muSCs) in aged mice .
|
-
-
- HY-P99446
-
|
TACI-Ig; TACI-Fc 5
|
TNF Receptor
|
Inflammation/Immunology
|
|
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .
|
-
-
- HY-150636
-
|
|
Autophagy
Apoptosis
|
Cancer
|
|
Autophagy-IN-1 is a potent autophagy/mitophagy inhibitor, acts by selectively increasing the autophagic flux while blocking the autophagosome-lysosome fusion in cancer cells. Autophagy-IN-1 can induce apoptosis and cell cycle arrest. Autophagy-IN-1 significantly inhibits tumor growth in an HCT116 xenograft mouse model and with low toxicity. Autophagy-IN-1 can be used for researching colorectal cancer .
|
-
-
- HY-P10517
-
|
SFT
|
HIV
|
Infection
|
|
Sifuvirtide (SFT) is a potent HIV fusion inhibitor. Sifuvirtide inhibits HIV-1 mediated cell fusion in a dose-dependent manner and is highly potent against infection by primary and laboratory-adapted HIV-1 isolates of multiple genotypes. Sifuvirtide can be used in the research of anti-HIV drugs .
|
-
-
- HY-148202
-
|
|
HIV
|
Infection
|
|
Influenza antiviral conjugate-1 (INT-2) is a HIV inhibitor, shows potent cell fusion inhibition . Influenza antiviral conjugate-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-146807
-
|
|
Trk Receptor
|
Cancer
|
|
Type II TRK inhibitor 1 is a potent TRK inhibitor, which inhibits various TRK fusion protein variants and wild type. Type II TRK inhibitor 1 exhibits antiproliferative activity against Ba/F3 cells harboring CD74-TRKA G667C and ETV6-TRKC G696C fusion proteins with IC50s of 6 nM and 1.7 nM, respectively . Type II TRK inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-P10308
-
|
|
HIV
|
Infection
|
|
[(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) is a selective inhibitor of HIV-1. [(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) inhibits viral infection and cell fusion by blocking the interaction between HIV-1 and CD4 molecules. [(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) can completely inhibit fusion formation at a concentration of 25 μM .
|
-
![[(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92)](//file.medchemexpress.eu/product_pic/hy-p10308.gif)
-
- HY-122204
-
|
|
HIV
|
Infection
|
|
5M038 is an inhibitor of HIV envelope-mediated fusion with potent inhibitory activity against gp41-mediated membrane fusion. 5M038 prevents the formation of the gp41 post-fusion conformation and inhibits envelope-mediated membrane fusion in cell-cell fusion and viral infectivity assays. 5M038 has shown broad fusion inhibition in tests against multiple HIV-1 subtypes, including M and T strains. 5M038 targets a highly conserved hydrophobic pocket and binds to the gp41 trimer, thereby exerting its inhibitory effect .
|
-
-
- HY-P4110
-
|
|
iGluR
|
Metabolic Disease
Inflammation/Immunology
|
|
TAT-NSF222 Fusion Peptide is a fusion polypeptide with two domains, a TAT domain, which enters cells through macropinocytosis, and an NSF domain that inhibits N-ethylmaleimide-sensitive factor (NSF). TAT-NSF222 Fusion Peptide is an exocytosis inhibitor .
|
-
-
- HY-P4108
-
|
|
Influenza Virus
|
Infection
|
|
TAT-HA2 Fusion Peptide is a peptide-based delivery agent that combines the pH-sensitive HA2 fusion peptide from Influenza and the cell-penetrating peptide TAT from HIV. TAT-HA2 Fusion Peptide is a transactivator of transcription and hemaglutanin for endosomal release. TAT-HA2 Fusion Peptide enhances cellular uptake of macromolecules .
|
-
-
- HY-76648
-
|
|
HIV
|
Infection
|
|
NBD-556, a CD4 mimetic, is a potent HIV-1 entry inhibitor that blocks the gp120-CD4 interaction. NBD-556 shows potent cell fusion and virus-cell fusion inhibitory activity at low micromolar levels .
|
-
-
- HY-P99667
-
|
OMP-54F28; FZD8-Fc
|
Wnt
|
Cancer
|
|
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
|
-
-
- HY-120190
-
|
|
Drug Metabolite
|
Infection
|
|
Citreoindole is a diketopiperazine metabolite isolated from a hybrid cell fusion of two strains of P. citreovirde that is cytotoxic in vitro against HeLa cells at 8.4 μM.
|
-
-
- HY-N7996
-
|
|
Bacterial
Fungal
|
Infection
|
|
Matairesinoside is a lignan with antibacterial and antioxidant activities. Matairesinoside also shows virus-cell fusion inhibitory activity .
|
-
-
- HY-B0795
-
|
|
mTOR
Autophagy
|
Cancer
|
|
MHY1485 is a potent cell-permeable mTOR activator that targets the ATP domain of mTOR. MHY1485 inhibits autophagy by suppression of fusion between autophagosomes and lysosomes .
|
-
-
- HY-W248118
-
|
PM556
|
Fluorescent Dye
|
Others
|
|
Pyrromethene 556 (PM556) is a green-fluorescent polar tracer dye. It is used for investigations of membrane fusion, lysis, and gap-junctional communication and to detect volume changes in cells or liposomes.
|
-
-
- HY-D1777
-
|
PM605
|
Fluorescent Dye
|
Others
|
|
Pyrromethene 605 (PM605) is a green-fluorescent polar tracer dye. It is used for investigations of membrane fusion, lysis, and gap-junctional communication and to detect volume changes in cells or liposomes.
|
-
-
- HY-W248583
-
|
PM650
|
Fluorescent Dye
|
Others
|
|
Pyrromethene 650 (PM650) is a green-fluorescent polar tracer dye. It is used for investigations of membrane fusion, lysis, and gap-junctional communication and to detect volume changes in cells or liposomes.
|
-
-
- HY-P99420
-
|
ALPN-101
|
CD28
|
Inflammation/Immunology
|
|
Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities .
|
-
-
- HY-P10651
-
|
|
Bacterial
|
Infection
|
|
Lifeact peptide is a fusion structure of BP100 bound to actin. BP100 (KKLFKKILKYL-amide) is an antimicrobial peptide against plant pathogens that acts as a fast and effective cell penetrant to transport fluorescent test cargo into the cytoplasm of plant cell walls .
|
-
-
- HY-D1672
-
|
|
Fluorescent Dye
|
Neurological Disease
|
|
TMR Biocytin is a polar tracer used in the research of cell-cell and cell-liposome fusions, as well as membrane permeability and cellular uptake during pinocytosis. TMR Biocytin can be detected using streptavidin, and is an effective neuronal tracer in live tissue (Ex=544 nm, Em=571 nm) .
|
-
-
- HY-P5497
-
|
|
HIV
|
Others
|
|
C34 peptide is a biological active peptide. (This C34 peptide, also known as HR2, belongs to the helical region of gp41 of HIV, C-terminal heptad repeat 2 (HR2) defined as C helix or C peptide. It is known that HIV-1 enters cells by membrane fusion, C34 gp41 peptide is a potent inhibitors of HIV-1 fusion.)
|
-
-
- HY-D1688
-
|
|
Fluorescent Dye
|
Others
|
|
Flubida-2 is a cell permeable dye which can be hydrolyzed to Fubi-2 by endoesterases in cells (after hydrolysis, Ex=492 nm, Em=517 nm). Flubida-2 can be used to detect pH at a specific site in a cell organelle by directing the probe to where avidin fusion proteins are located .
|
-
-
- HY-103300
-
|
|
Endogenous Metabolite
|
Infection
|
|
NPE-caged-proton is a reagent that releases protons under UV light and has the activity of activating the fusion protein GP64 under weak acidic conditions. NPE-caged-proton can promote the binding of enveloped viruses to liposome membranes with acidic phospholipids in an environment of pH 4.0 to 5.5, thereby initiating membrane fusion. The ultraviolet unblocking effect of NPE-caged-proton can lower the environmental pH, thereby triggering the process of viral membrane fusion. When studying the interaction between viruses and cell membranes, NPE-caged-proton provides a valuable tool for revealing the subtle behaviors of viruses in different chemical and biochemical environments .
|
-
-
- HY-D2317
-
|
|
Fluorescent Dye
|
Others
|
|
HaloFlipper 30 is a fluorescent probe that covalently reacts with HaloTag fusion proteins to form an ester bond, which allows the probe to be stably attached to membrane structures. HaloFlipper 30 has high specificity, precision and good cell permeability .
|
-
-
- HY-P991344
-
|
|
PD-1/PD-L1
|
Cancer
|
|
AMP-224 is a fusion protein targeting PD-L2. AMP-224 specifically binds to PD-1 T cells (chronically stimulated/exhausted T cells). AMP-224 can be used in Colorectal cancer and Solid tumours research .
|
-
-
- HY-13992
-
|
B/B Homodimerizer
|
FKBP
|
Metabolic Disease
|
|
AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.
|
-
-
- HY-P990706
-
|
ALPN-303
|
TNF Receptor
|
Inflammation/Immunology
|
|
Povetacicept (ALPN-303), an Fc fusion protein of an engineered TACI domain, is a dual APRIL/BAFF antagonist. Povetacicept modulates B lymphocytes and pathogenic autoantibodies for the study of Lupus and other B cell-related autoimmune diseases .
|
-
-
- HY-P99480
-
|
M7824; MSB0011359C
|
TGF-β Receptor
|
Cancer
|
|
Bintrafusp alfa (M 7824) is a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII fused to a human IgG1 mAb blocking programmed cell death ligand. Bintrafusp alfa can be used for the research of cancer .
|
-
-
- HY-P990708
-
|
MDNA55; NBI-3001; PRX-321
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Bizaxofusp (MDNA55) is a fusion protein formed by the linkage of IL-4 and a truncated Pseudomonas exotoxin. Bizaxofusp can bind to IL-4 receptors on the surface of tumor cells and be internalized, and its exotoxin moiety can inhibit protein synthesis and induce tumor cell apoptosis. Bizaxofusp can be used in the study of cancer .
|
-
-
- HY-P991214
-
|
EMD 273066; huKS-IL2
|
Interleukin Related
|
Cancer
|
|
Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine fusion agent targeting the epithelial cell adhesion molecule (EpCAM). Tucotuzumab celmoleukin binds to EpCAM and delivers IL-2 to the tumor microenvironment, which can activate cytotoxic effector cells, such as CD8+ T cells and natural killer (NK) cells. Tucotuzumab celmoleukin is promising for research of EpCAM-positive cancers, such as colorectal cancer and prostate cancer .
|
-
-
- HY-176269
-
|
|
Bcr-Abl
ERK
STAT
PARP
Caspase
Apoptosis
|
Cancer
|
|
VS1150 (Compound 11) is a BCR-ABL-targeting phosphorylation-inducing chimeric small molecule (PHICS). VS1150 significantly inhibits oncogenic kinase BCR-ABL signaling by inducing inhibitory phosphorylation at its Y253 (EC50: 69 nM), subsequently triggering cell apoptosis. VS1150 also inhibits other oncogenic ABL fusions and drug-resistant mutants like T315I. VS1150 can be used for chronic myeloid leukemia (CML) and other ABL fusion-driven cancers research .
|
-
-
- HY-128347
-
|
|
Epigenetic Reader Domain
|
Inflammation/Immunology
Cancer
|
|
M-89 is a highly potent and specific menin inhibitor, with a Kd of 1.4 nM for binding to menin. M-89 inhibits the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction and has potential to treat MLL leukemia. M-89 inhibits the cell growth in leukemia cell lines carrying MLL fusion .
|
-
-
- HY-P991087
-
|
|
FAP
|
Cancer
|
|
RO7122290 is a bispecific fusion protein carrying a split trimeric 4-1BB (CD137) ligand and a fibroblast activation protein α (FAP) binding site. O7122290 is a FAP-α-targeted 4-1BB agonist that costimulates T cells for improved tumor cell killing in FAP-expressing tumors .
|
-
-
- HY-129047
-
|
|
Ser/Thr Protease
Protease Activated Receptor (PAR)
|
Infection
Inflammation/Immunology
|
|
Trypsin is a serine protease enzyme, and hydrolyzes proteins at the carboxyl side of the Lysine or Arginine. Trypsin activates PAR2 and PAR4. Trypsin induces cell-to-cell membrane fusion in PDCoV infection by the interaction of S glycoprotein of PDCoV and pAPN. Trypsin also promotes cell proliferation and differentiation. Trypsin can be used in the research of wound healing and neurogenic inflammation .
|
-
-
- HY-P99752
-
|
ALKS 4230; RDB-1450
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer .
|
-
-
- HY-P4109A
-
|
NT21MP TFA; V1 peptide TFA
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
vMIP-II (1-21) (NT21MP) TFA is an inhibitor of CXCR4. vMIP-II (1-21) TFA interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) TFA inhibits CXCR4 by competing with 125I-SDF-1R for binding sites (IC50=190 nM) .
|
-
-
- HY-P4109
-
|
NT21MP; V1 peptide
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
vMIP-II (1-21) (NT21MP) is an inhibitor of CXCR4. vMIP-II (1-21) interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) inhibits CXCR4 by competing with 125I-SDF-1R for binding sites (IC50=190 nM) .
|
-
-
- HY-P99339
-
|
IMCgp100
|
Interleukin Related
TNF Receptor
|
Cancer
|
|
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .
|
-
-
- HY-P0175A
-
|
740YPDGFR TFA; PDGFR 740Y-P TFA
|
PI3K
Autophagy
|
Cancer
|
|
740 Y-P TFA is a potent and cell-permeable PI3K activator. 740 Y-P TFA readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
|
-
-
- HY-P1566
-
|
|
HIV
|
Infection
|
|
MPG, HIV related is 27-aa peptide, derived from both the nuclear localisation sequence of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41 and is a potent delivery agent for the generalised delivery of nucleic acids and of oligonucleotides into cultured cells.
|
-
-
- HY-139533
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Phosphatidylinositols, soya, sodium salts is a mixture of phosphatidylinositols. Phosphoinositides are lipids involved in the vesicular transport of proteins and lipids between the different compartments of eukaryotic cells. They act by recruiting and/or activating effector proteins and thus are involved in regulating various cellular functions, such as vesicular budding, membrane fusion and cytoskeleton dynamics .
|
-
-
- HY-144321
-
|
|
Trk Receptor
|
Cancer
|
|
Trk-IN-9 (Compound 12) is a potent inhibitor of TRK. Trk-IN-9 inhibits the proliferation of Km-12 cell lines. Trk-IN-9 induces the apoptosis of Km-12 cells in a concentration-dependent manner. Trk-IN-9 inhibits the phosphorylation of TRK to block downstream pathways. Trk-IN-9 has the potential for the research of NTRK-fusion cancers .
|
-
-
- HY-19587
-
|
NSC335153
|
DNA/RNA Synthesis
|
Cancer
|
|
Ditercalinium chloride is an anticancer agent. Ditercalinium chloride inhibits human DNA polymerase gamma activity. Ditercalinium chloride can deplete mitochondrial DNA in both mouse and human cells. Ditercalinium chloride is a potential ligand against the COMMD10-AP3S1 fusion protein .
|
-
-
- HY-P5307
-
|
INF7-A5K-TAT
|
Biochemical Assay Reagents
|
Others
|
|
Peptide A5K (INF7-A5K-TAT) is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .
|
-
-
- HY-P5307A
-
|
INF7-A5K-TAT acetate
|
Biochemical Assay Reagents
|
Others
|
|
Peptide A5K (INF7-A5K-TAT) acetate is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K acetate can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K acetate enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .
|
-
-
- HY-129047A
-
|
|
Ser/Thr Protease
Protease Activated Receptor (PAR)
|
Infection
Inflammation/Immunology
|
|
Trypsin MS grade is a serine protease enzyme, and hydrolyzes proteins at the carboxyl side of the Lysine or Arginine. Trypsin MS grade activates PAR2 and PAR4. Trypsin MS grade induces cell-to-cell membrane fusion in PDCoV infection by the interaction of S glycoprotein of PDCoV and pAPN. Trypsin MS grade also promotes cell proliferation and differentiation. Trypsin MS grade can be used in the research of wound healing and neurogenic inflammation .
|
-
-
- HY-171983
-
|
|
RSV
|
Infection
|
|
RSV-IN-13 (compound 24) is a selective RSV fusion protein inhibitor with antiviral activity. RSV-IN-13 has an EC50 of 444.2 nM against RSV A2 strain and a CC90 of 23.7 μM in HepG2 cells. RSV-IN-13 can block the virus from entering host cells. RSV-IN-13 can be used to study RSV infection .
|
-
-
- HY-141429
-
|
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
|
AS-99 is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 µM, Kd= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
|
-
- HY-141429C
-
|
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
|
AS-99 is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 μM, Kd= 0.89 μM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
|
-
- HY-P10804
-
|
|
SARS-CoV
|
Infection
|
|
PIH is an antiviral peptide that effectively inhibits the HR1/HR2-mediated membrane fusion between MERS-CoV and host cells, with an IC50 of 1.171 μM. By forming a complex with gold nanorods (AuNRs), the antiviral efficacy of PIH can be further enhanced by 10-fold .
|
-
- HY-108847
-
|
|
TNF Receptor
Bacterial
|
Inflammation/Immunology
Cancer
|
|
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .
|
-
- HY-P0175
-
|
740YPDGFR; PDGFR 740Y-P
|
PI3K
Autophagy
|
Cancer
|
|
740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
|
-
- HY-13491
-
|
|
Trk Receptor
|
Cancer
|
|
GNF-5837 is a potent, selective, and orally bioavailable pan-tropomyosin receptor kinase (TRK) inhibitor which display antiproliferative effects in cellular Ba/F3 assays ( IC50 values of 7 nM, 9 nM and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively) .
|
-
- HY-108829
-
|
CTLA4lg; BMS-188667
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
|
-
- HY-141429A
-
|
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
|
AS-99 TFA is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 μM, Kd= 0.89 μM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
|
-
- HY-14904A
-
|
|
Influenza Virus
SARS-CoV
|
Infection
|
|
Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells . Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .
|
-
- HY-159147
-
|
|
PROTACs
ROS Kinase
Apoptosis
|
Cancer
|
|
SIAIS039 is an orally active c-ros oncogene 1 (ROS1)-specific PROTAC with DC50s of 154.46 nM, 126.47 nM, 143.69 nM for HCC78 cells, Ba/F3 expressing the CD74-ROS1 fusion and Ba/F3 expressing the SDC4-ROS1 fusion, respectively. SIAIS039 suppresses cell proliferation, induces cell cycle arrest and apoptosis, and inhibits clonogenicity against ROS1-positive cells. SIAIS039 demonstrates anti-tumour effects against ROS1-driven tumor growth vivo. SIAIS039 is composed of the ALK inhibitor Brigatinib (HY-12857), a linker EM-12 (HY-138793), and a VHL ligand E3 ubiquitin ligase 1-Butyne (Red: Brigatinib; Blue: VHL ligand; Black: linker) .
|
-
- HY-152100
-
|
|
Autophagy
|
Cancer
|
|
CUR5g is a potent autophagy inhibitor. CUR5g selectively inhibits autophagosome degradation in cancer cells by blocking autophagosome-lysosome fusion. CUR5g blocks the recruitment of STX17 to autophagosomes via a UVRAG-dependent mechanism, resulting in the inability of autophagosomes to fuse with lysosomes. CUR5g improves the anticancer effect of Cisplatin (HY-17394) against A549 cells both in vitro and in vivo .
|
-
- HY-108829A
-
|
CTLA4lg (powder); BMS-188667 (powder)
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
|
-
- HY-P99879
-
|
Benegrastim; Bineuta; F 627
|
STAT
|
Inflammation/Immunology
|
|
Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2)-Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells .
|
-
- HY-123985
-
|
|
Mitochondrial Metabolism
|
Others
|
|
MFN2 agonist-1 (B-A/l) potently stimulates mitochondrial fusion in mitofusin 2 (MFN2)-deficient cells. MFN2 agonist-1 reverses mitochondrial “clumping” (formation of static mitochondrial aggregates) and restores mitochondrial motility in cultured mouse neurons expressing the CMT2A mutant MFN2 T105M.
|
-
- HY-168616
-
|
|
RSV
IGF-1R
|
Infection
|
|
CL-A3-7 is a virus-cell fusion inhibitor targeting the RSV F protein. It exerts its effect by blocking the interaction between the virus and the host IGF1R, effectively inhibiting infections of both wild-type RSV and the K394R variant. It is applicable to anti-RSV drug development and resistance-related research .
|
-
- HY-P99687
-
|
AMG 256
|
PD-1/PD-L1
|
Cancer
|
|
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research .Latikafusp may lead to the development of immunogenicity-mediated responses .
|
-
- HY-P99759
-
|
IL-15N72D
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Nogapendekin alfa (his tag), a soluble protein subunit of a human interleukin (IL)-15 variant, is a superagonist of IL-15. Nogapendekin alfa (his tag) promotes the proliferation and viability of immune cells. Nogapendekin alfa (his tag) combines with Inbakicept (HY-P99661) at a ratio of 2:1, to form N-803 (Nogapendekin alfa inbakicept), an IL-15 cytokine antibody fusion protein. N-803 reduces tumor burden by activation of NK cells and CD8 + T cells .
|
-
- HY-P990017
-
|
CD19-4-1BBL; RO7227166; RG6076
|
CD19
|
Cancer
|
|
Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells .
|
-
- HY-172714A
-
|
|
Liposome
|
Infection
|
|
DSPE-PEG3400-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .
|
-
- HY-172714
-
|
|
Liposome
|
Infection
|
|
DSPE-PEG2000-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .
|
-
- HY-172713
-
|
|
Liposome
|
Infection
|
|
DSPE-PEG1000-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .
|
-
- HY-P99844
-
|
ALPN-202; CD80 vIgD-Fc
|
CTLA-4
|
Cancer
|
|
Davoceticept (ALPN-202; CD80 vIgD-Fc) is a variant CD80 vIgD-Fc fusion protein targeting CTLA-4 and PD-L1. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .
|
-
- HY-B1336
-
|
|
Bacterial
Apoptosis
Antibiotic
Parasite
|
Infection
Cancer
|
|
Furazolidone is a monoamine oxidase (MAO) inhibitor with antiproliferative, apoptosis-inducing and differentiation-promoting activities. Furazolidone may inhibit leukemia fusion protein-mediated bone marrow transformation by upregulating the stability of the tumor suppressor protein p53. Furazolidone exhibits anti-leukemic activity in acute myeloid leukemia (AML) cell lines and can be used for anti-AML research [2].
|
-
- HY-P99568
-
|
RC18
|
TNF Receptor
|
Inflammation/Immunology
|
|
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease . The component ratio of this product is Active ingredient : Excipients = 1: 0.5-1: 0.8.
|
-
- HY-14904
-
|
|
SARS-CoV
Influenza Virus
|
Infection
|
|
Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an anti-influenza virus agent. Umifenovir could effectively inhibit the fusion of virus with host cells . Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro . Umifenovir shows anti-inflammatory activity .
|
-
- HY-167897
-
|
|
Histamine Receptor
|
Neurological Disease
|
|
UR-AK49 (compound 11) is a human histamine H1 and H2 receptor agonist. UR-AK49 has an EC50 of 23 nM in a GTPase assay with hH2R-Gsalpha fusion protein expressed in Sf9 insect cells. UR-AK49 can be used in neuro-related research .
|
-
- HY-172715
-
|
|
Liposome
|
Infection
|
|
DSPE-PEG5000-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .
|
-
- HY-153331
-
|
|
WDR5
|
Cancer
|
|
DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC50 of 29 nM and a Kd value of 72.9 nM for the WDR5 protein. DDO-2213 selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. DDO-2213 can be used for MLL fusion leukemia research .
|
-
- HY-N10177
-
|
|
HSV
|
Infection
|
|
Peniterphenyl A is a natural product obtained from a deep-sea-derived Penicillium sp. Peniterphenyl A inhibits HSV-1/2 virus entry into cells and may block HSV-1/2 infection through direct interaction with virus envelope glycoprotein D to interfere with virus adsorption and membrane fusion. Peniterphenyl A is a promising lead compound against HSV-1/2 .
|
-
- HY-14904AS
-
|
|
Isotope-Labeled Compounds
Influenza Virus
SARS-CoV
|
Infection
|
|
Umifenovir-d6 (hydrochloride) is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells . Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .
|
-
- HY-W250118
-
|
|
Liposome
Autophagy
|
Neurological Disease
Metabolic Disease
|
|
Phosphatidylethanolamine is an orally active phospholipid widely present in organisms. Phosphatidylethanolamine participates in the formation of autophagosome membrane as a lipid anchor of autophagy-related protein Atg8/LC3. Phosphatidylethanolamine enhances Autophagic flux, promotes cell differentiation, regulates lipid droplet fusion, delays aging, and also affects lipid metabolism and membrane integrity .
|
-
- HY-100558
-
Bafilomycin A1
Maximum Cited Publications
591 Publications Verification
BafA1
|
Proton Pump
Autophagy
Antibiotic
Bacterial
Apoptosis
|
Infection
Cancer
|
|
Bafilomycin A1 (BafA1) is a specific and reversible inhibitor of vacuolar H +-ATPase (V-ATPase) with IC50 values of 4-400 nmol/mg. Bafilomycin A1, a macrolide antibiotic, is also used as an autophagy inhibitor at the late stage. Bafilomycin A1 blocks autophagosome-lysosome fusion and inhibits acidification and protein degradation in lysosomes of cultured cells. Bafilomycin A1 induces apoptosis .
|
-
- HY-153083
-
|
|
SARS-CoV
mRNA
|
Infection
|
|
COVID-19 Spike Protein mRNA will express COVID-19 spike protein, and suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 spike protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 spike protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 spike protein is an important site of action for host neutralizing antibodies and a key target for vaccine design .
|
-
- HY-12220
-
MM-102
4 Publications Verification
HMTase Inhibitor IX
|
WDR5
Apoptosis
NF-κB
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
MM-102 (HMTase Inhibitor IX) is a cell-permeable and tightly binding inhibitor of MLL1-WDR5 interaction (IC50=2.4 nM). MM-102 can specifically inhibit the growth and induce apoptosis of leukemia cells containing MLL1 fusion protein, and reduce renal fibrosis and inflammation in mice with ischemia-reperfusion injury. In addition, MM-102 also acts as an H3K4 histone methyltransferase inhibitor to improve the development of porcine somatic cell nuclear transfer (SCNT) embryos .
|
-
- HY-124582
-
NEO214
1 Publications Verification
|
Autophagy
mTOR
|
Cancer
|
|
NEO214 is an autophagy inhibitor and a covalent conjugate of the PDE4 inhibitor Rolipram (HY-16900) and perillyl alcohol (HY-N7000). It has anti-cancer activity and blood-brain barrier (BBB) permeability. Over sex. NEO214 prevents autophagy-lysosome fusion, thereby blocking autophagic flux and triggering glioma cell death. The process involves mTOR activation, andTFEB(Transcription Factor EB) aggregation. NEO214 inhibitionMacroautophagy/autophagy in glioblastoma cells has the potential to overcome chemotherapy resistance in glioblastoma .
|
-
- HY-14904AR
-
|
|
Reference Standards
Influenza Virus
SARS-CoV
|
Infection
|
|
Umifenovir (hydrochloride) (Standard) is the analytical standard of Umifenovir (hydrochloride). This product is intended for research and analytical applications. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells . Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .
|
-
- HY-P5320
-
|
|
Apoptosis
|
Others
|
|
TAT-BH4 (Bcl-xL) localized mainly at the mitochondria, prevents apoptotic cell death. TAT-BH4 (Bcl-xL) is a fusion peptide that combines the N-terminal cysteine conjugated protein transduction domain of HIV TAT protein (amino acids 49 to 57) with the Bcl-xL BH4 peptide. TAT-BH4 can be used for research of diseases caused by accelerated apoptosis .
|
-
- HY-B1152
-
|
|
Dopamine Receptor
CD276/B7-H3
FOXO
|
Neurological Disease
Cancer
|
|
Piperacetazine is an orally active dopamine receptor antagonist and phenothiazine antipsychotic. Piperacetazine can directly bind to the PAX3::FOXO1 fusion protein and inhibit its transcriptional activity. Piperacetazine also exhibits antitumor activity with an IC50 of 7.627 μM against PANC-1 cells. Piperacetazine can be used for the research of diseases such as schizophrenia and pancreatic cancer and other tumors .
|
-
- HY-W127378
-
|
1,2-Dioleoyl-3-trimethylammonium-propane methylsulfate
|
Liposome
|
Others
|
|
DOTAP methylsulfat is a cationic lipid reagent, a cationic derivative of trimethylammonium, linked to two 18-carbon fatty acid tails, each with a single olefin group. DOTAP methylsulfat can self-assemble with negatively charged ions (such as DNA) to form complexes, which can be adsorbed to the cell membrane surface and enter the cell by electrostatic interaction and endocytosis, respectively. DOTAP methylsulfat promotes endosomal membrane fusion with its own hydrophobic domain, releases DNA into the cytoplasm, and exerts gene delivery function. DOTAP methylsulfat can be widely used in research fields such as gene therapy, cell transfection, and non-viral vector design[1][2].
|
-
- HY-P5320A
-
|
|
Apoptosis
|
Others
|
|
TAT-BH4 (Bcl-xL) TFA is localized mainly at the mitochondria, prevents apoptotic cell death. TAT-BH4 (Bcl-xL) is a fusion peptide that combines the N-terminal cysteine conjugated protein transduction domain of HIV TAT protein (amino acids 49 to 57) with the Bcl-xL BH4 peptide. TAT-BH4 TFA can be used for research of diseases caused by accelerated apoptosis .
|
-
- HY-P99459
-
|
BG 9924; TT-47
|
TNF Receptor
|
Inflammation/Immunology
|
|
Baminercept (BG 9924) is an anti-lymphotoxin β receptor (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA) .
|
-
- HY-14904R
-
|
|
Reference Standards
SARS-CoV
Influenza Virus
|
Infection
|
|
Umifenovir (Standard) is the analytical standard of Umifenovir. This product is intended for research and analytical applications. Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an anti-influenza virus agent. Umifenovir could effectively inhibit the fusion of virus with host cells . Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro . Umifenovir shows anti-inflammatory activity .
|
-
- HY-P99803
-
|
VAL-1221
|
Glycosidase
|
Others
|
|
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
|
-
- HY-161819
-
|
|
Trk Receptor
|
Cancer
|
|
TRK-IN-29 (Compound B31) is a second-generation TRK inhibitor (IC50: 9 nM, 0.6 nM, 18 nM, 5 nM, 6 nM for TRKA G595R, TRKA F589L, TRKA G667C, TRKA and TRKC respectively). TRK-IN-29 inhibits the phosphorylation of TRKA. TRK-IN-29 has good antiproliferative activities against NTRK fusion positive cells. TRK-IN-29 has exellent plasma stability and moderate pharmacokinetic properties .
|
-
- HY-P10993
-
|
|
Bcl-2 Family
|
Cancer
|
|
CT20p is an anticancer peptide based on the C hydrophobic terminus of Bax. CT20p has a unique cytotoxic effect independent of full-length Bax, and can act on mitochondria, leading to fusion-like aggregation and mitochondrial membrane hyperpolarization. CT20p can reduce α5β1 integrin levels and inhibit F-actin polymerization, thereby destroying the cytoskeleton and preventing cell attachment. CT20p can be used in the study of breast cancer .
|
-
- HY-168551
-
|
|
PROTACs
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
PROTAC ALK degrader-3 (4B) is an orally active ALK degrader based on PROTACs, which can effectively induce persistent degradation of ALK fusion protein in Karpas 299 cells and strong inhibition of downstream pathways,IC50 is 119.33 nM. PROTAC ALK degrader-3 exhibits antitumor activity. (Structure Note: PINK, ALK Inhibitor (HY-15656); Blue, E3 (HY-W023573); Black, linker (HY-168552)) .
|
-
- HY-P99661
-
|
|
Interleukin Related
|
Cancer
|
|
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .
|
-
- HY-163004
-
|
|
Trk Receptor
|
Cancer
|
|
Type II TRK inhibitor 2 (compound 40l) is a selective type II TRK inhibitor with plasma stability and moderate hepatic microsomal stability. Type II TRK inhibitor 2 significantly inhibits Km-12, Ba/F3-TRKA G595R and Ba/F3-TRKA G667C cell proliferation (IC50: 4.1 nM, 41.5 nM, 1.4 nM). Type II TRK inhibitor 2 can be used to study NTRK fusion cancers .
|
-
- HY-145795
-
|
|
Liposome
|
Others
|
|
OF-02 is an ionizable lipid for mRNA delivery and a key component of lipid nanoparticles (LNPs). OF-02 is protonated in the acidic endosomal environment to promote endosomal escape of mRNA and efficiently induce protein expression in target cells. OF-02 relies on the pH-responsive membrane fusion properties to form a complex with mRNA and destroy the endosomal membrane structure to achieve mRNA release in the cytoplasm. OF-02 is mainly used in the development of mRNA vaccines, gene editing, and protein replacement therapy[1][2][3].
|
-
- HY-P5395
-
|
|
HIV
|
Others
|
|
TAT-GluR23A Fusion Peptide is a biological active peptide. (This is the GluR23A sequence, a control inactive peptide used as a mutant counterpart to glutamate receptor endocytosis inhibitor (GluR23Y), connected to an 11 amino acid cell permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). GluR23A is derived from GluR23Y amino acids 869 to 877, with Ala substituted for Tyr, and thus lacking essential phosphorylation sites.Control peptide of HY-P2259)
|
-
- HY-137465
-
|
|
PROTACs
Trk Receptor
|
Cancer
|
|
CG428 is a potent and selective tropomyosin receptor kinase (TRK) PROTAC degrader that has anti-tumor activity. CG428 reduces levels of the tropomyosin 3 (TPM3)-TRKA fusion protein in KM12 colorectal carcinoma cells (DC50 = 0.36 nM) and inhibits downstream PLCγ1phosphorylation (IC50 = 0.33 nM). CG428 has a higher binding affinity for TRKA than TRKB and TRKC (Kd = 1 nM, 28 nM and 4.2 nM, respectively). In addition, CG428 effectively inhibits KM12 cell growth (IC50 = 2.9 nM) .(Pink: TRK inhibitor (HY-118271); Black: linker (HY-W067489); Blue: CRBN Ligand (HY-41547))
|
-
- HY-P991234
-
|
|
EGFR
p38 MAPK
PI3K
Akt
|
Cancer
|
|
COVA208 is a bispecific FynomAb (a fusion protein of an antibody and a Fyn SH3-derived binding protein) that targets HER2. COVA208 induces the degradation of HER2, reduces the levels of HER2, HER3, and EGFR, thereby effectively blocking the downstream signaling pathways of HER2, including the HER3-PI3K-AKT and MAPK pathways, and simultaneously inducing apoptosis of tumor cells. COVA208 is promising for research of cancers, such as HER2-positive breast cancer, gastric cancer, and colorectal cancer .
|
-
- HY-P10976
-
|
|
SARS-CoV
|
Infection
|
|
Spike Glycoprotein (1147-1162) is a linear and broadly neutralizing peptide in the S2 protein of SARS-CoV-2. Spike Glycoprotein (1147-1162) is conserved across SARS-CoV, BatCoV RaTG13, SARS-CoV-2, and SARS-CoV-2 variants. Spike Glycoprotein (1147-1162)-targeting mAbs can neutralize both SARS-CoV-2 and SARS-CoV by preventing fusion between the virus and cell membrane. Spike Glycoprotein (1147-1162) can be used for universal vaccines against SARS-CoV-2 mutants research .
|
-
- HY-174367
-
|
|
RUNX
Apoptosis
|
Cancer
|
|
RUNX1/ETO-IN-1 is a RUNX1-ETO oncogenic fusion protein inhibitor that specifically targets the NHR2 oligomerization domain. RUNX1/ETO-IN-1 directly interacts with the NHR2 (KD,app = 39 μM). RUNX1/ETO-IN-1 exhibits anti-leukemic activity by inducing apoptosis and promoting differentiation in RUNX1/ETO-translocated AML cells. RUNX1/ETO-IN-1 remains essentially uncharged at physiological pH, demonstrating superior membrane permeability.
|
-
- HY-P991524
-
|
|
EGFR
|
Cancer
|
|
MM-111 is a bispecific antibody fusion protein targeting the ErbB2/ErbB3 oncogenic unit. MM-111 blocks activation of the PI3K pro-survival pathway. MM-111 binds to the ErbB2 receptor, which localizes the bispecific molecule to ErbB2 over-expressing tumor cells and promotes binding of the anti-ErbB3 arm to the ErbB3 receptor. MM-111 binding to ErbB3 results in inhibition of ErbB3 signaling by blocking the binding of the ErbB3 physiological ligand heregulin. MM-111 can be used for the study of ErbB2 over-expressing breast tumors .
|
-
- HY-174315
-
|
|
PROTACs
Anaplastic lymphoma kinase (ALK)
Akt
ERK
|
Cancer
|
|
WZH-17-002 is a WZH-15-125-based ALK PROTAC degrader with a DC50 of 25 nM. WZH-17-002 enhances activities against Lorlatinib (HY-12215)-resistant ALK compound mutations. WZH-17-002 significantly reduces drug resistance in ALK-fusion non-small cell lung cancer (NSCLC) and inhibits tumor growth in EML4-ALK G1202R/L1196 M xenograft mice model . Pink: ALK ligand (HY-174314); Blue: CRBN ligase ligand (HY-14658); Black: linker (HY-174316)
|
-
- HY-P2200
-
|
BMY-29304
|
HIV
Antibiotic
|
Infection
Inflammation/Immunology
|
|
Siamycin I (BMY-29304), a 21-residue tricyclic peptide, is a secondary metabolite in actinomycetes. Siamycin I is a HIV fusion inhibitor with ED50s of 0.05 to 5.7 μM for acute HIV type 1 (HIV-1) and HIV-2 infections. Siamycin I inhibits the gelatinase and gelatinase biosynthesis-activating pheromone (GBAP) signaling via the FsrC-FsrA two-component regulatory system in a noncompetitive manner. Siamycin I suppresses the expression of both fsrBDC and gelE-sprE transcripts. Siamycin I, a lasso peptide, interacts with lipid II and inhibits cell wall biosynthesis. Siamycin I, an antibiotic, has the potential for enterococcal infections research .
|
-
- HY-113225B
-
|
GTP tritris
|
Endogenous Metabolite
|
Cancer
|
|
Guanosine triphosphate tritris (GTP tritris) serves as a vital enhancer of myogenic cell differentiation and plays a critical role in modulating miRNA-myogenic regulator factors. It also facilitates the release of exosomes enriched with guanosine and guanosine-derived molecules, and is regarded as an activated precursor for RNA synthesis. In mitochondrial function, GTP participates in the import of proteins into the matrix, which is essential for various regulated pathways, and is involved in initiating peptide synthesis through the binding of formylmethionyl-tRNA to the ribosome, as well as polypeptide chain elongation. Additionally, GTP acts as a phosphate and pyrophosphate carrier that channels chemical energy into specific biosynthetic pathways. It activates signal transducing G proteins that regulate cellular processes such as proliferation and differentiation, and its hydrolysis by small GTPases, including Ras and Rho, is integral to both proliferation and apoptosis. Furthermore, the small GTPase Rab is instrumental in vesicle docking, fusion, and formation. Beyond signal transduction, GTP is an energy-rich precursor in the enzymatic biosynthesis of DNA and RNA.
|
-
- HY-174981
-
|
|
PROTACs
FGFR
ATP Synthase
|
Cancer
|
|
LC-MF-4 is a selective FGFR3 PROTAC degrader with a DC50 of 30.89 nM in KMS-11 cells. LC-MF-4 inhibits the metabolic function of FGFR3-TACC3 fusion positive cancers with reduction of ATP synthesis and inhibition of mitochondrial biogenesis genes. LC-MF-4 has potent antitumor activity in the Ba/F3-FGFR3-TACC3 xenograft mice model. LC-MF-4 can be used for FGFR3-altered cancers like bladder cancer and urothelial carcinoma (UC) research . Pink: FGFR3 ligand (HY-175414); Blue: VHL ligase ligand (HY-125905); Black: linker (HY-Y1224)
|
-
-
-
HY-L075
-
|
|
2,352 compounds
|
|
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.
As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.
MCE offers a unique collection of 2,352 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.
|
| Cat. No. |
Product Name |
Type |
-
- HY-W248118
-
|
PM556
|
Fluorescent Dyes/Probes
|
|
Pyrromethene 556 (PM556) is a green-fluorescent polar tracer dye. It is used for investigations of membrane fusion, lysis, and gap-junctional communication and to detect volume changes in cells or liposomes.
|
-
- HY-W248583
-
|
PM650
|
Dyes
|
|
Pyrromethene 650 (PM650) is a green-fluorescent polar tracer dye. It is used for investigations of membrane fusion, lysis, and gap-junctional communication and to detect volume changes in cells or liposomes.
|
-
- HY-D1777
-
|
PM605
|
Fluorescent Dyes/Probes
|
|
Pyrromethene 605 (PM605) is a green-fluorescent polar tracer dye. It is used for investigations of membrane fusion, lysis, and gap-junctional communication and to detect volume changes in cells or liposomes.
|
-
- HY-D1672
-
|
|
Fluorescent Dyes/Probes
|
|
TMR Biocytin is a polar tracer used in the research of cell-cell and cell-liposome fusions, as well as membrane permeability and cellular uptake during pinocytosis. TMR Biocytin can be detected using streptavidin, and is an effective neuronal tracer in live tissue (Ex=544 nm, Em=571 nm) .
|
-
- HY-D1688
-
|
|
Fluorescent Dyes/Probes
|
|
Flubida-2 is a cell permeable dye which can be hydrolyzed to Fubi-2 by endoesterases in cells (after hydrolysis, Ex=492 nm, Em=517 nm). Flubida-2 can be used to detect pH at a specific site in a cell organelle by directing the probe to where avidin fusion proteins are located .
|
-
- HY-D2317
-
|
|
Fluorescent Dyes/Probes
|
|
HaloFlipper 30 is a fluorescent probe that covalently reacts with HaloTag fusion proteins to form an ester bond, which allows the probe to be stably attached to membrane structures. HaloFlipper 30 has high specificity, precision and good cell permeability .
|
| Cat. No. |
Product Name |
Type |
-
- HY-W250118
-
|
|
Drug Delivery
|
|
Phosphatidylethanolamine is an orally active phospholipid widely present in organisms. Phosphatidylethanolamine participates in the formation of autophagosome membrane as a lipid anchor of autophagy-related protein Atg8/LC3. Phosphatidylethanolamine enhances Autophagic flux, promotes cell differentiation, regulates lipid droplet fusion, delays aging, and also affects lipid metabolism and membrane integrity .
|
-
- HY-W127378
-
|
1,2-Dioleoyl-3-trimethylammonium-propane methylsulfate
|
Drug Delivery
|
|
DOTAP methylsulfat is a cationic lipid reagent, a cationic derivative of trimethylammonium, linked to two 18-carbon fatty acid tails, each with a single olefin group. DOTAP methylsulfat can self-assemble with negatively charged ions (such as DNA) to form complexes, which can be adsorbed to the cell membrane surface and enter the cell by electrostatic interaction and endocytosis, respectively. DOTAP methylsulfat promotes endosomal membrane fusion with its own hydrophobic domain, releases DNA into the cytoplasm, and exerts gene delivery function. DOTAP methylsulfat can be widely used in research fields such as gene therapy, cell transfection, and non-viral vector design[1][2].
|
-
- HY-145795
-
|
|
Drug Delivery
|
|
OF-02 is an ionizable lipid for mRNA delivery and a key component of lipid nanoparticles (LNPs). OF-02 is protonated in the acidic endosomal environment to promote endosomal escape of mRNA and efficiently induce protein expression in target cells. OF-02 relies on the pH-responsive membrane fusion properties to form a complex with mRNA and destroy the endosomal membrane structure to achieve mRNA release in the cytoplasm. OF-02 is mainly used in the development of mRNA vaccines, gene editing, and protein replacement therapy[1][2][3].
|
-
- HY-172714A
-
|
|
Drug Delivery
|
|
DSPE-PEG3400-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .
|
-
- HY-172714
-
|
|
Drug Delivery
|
|
DSPE-PEG2000-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .
|
-
- HY-172713
-
|
|
Drug Delivery
|
|
DSPE-PEG1000-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .
|
-
- HY-172715
-
|
|
Drug Delivery
|
|
DSPE-PEG5000-MPG is a PEG compound which composed of DSPE and a peptide vector (MPG). MPG is derived from both the nuclear localisation sequence (NLS) of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41. MPG could deliver short oligonucleotides into cells efficiently and independently of the endosomal pathway .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10517A
-
|
SFT acetate
|
HIV
|
Infection
|
|
Sifuvirtide (SFT) acetate is a potent HIV fusion inhibitor. Sifuvirtide acetate inhibits HIV-1 mediated cell fusion in a dose-dependent manner and is highly potent against infection by primary and laboratory-adapted HIV-1 isolates of multiple genotypes. Sifuvirtide acetate can be used in the research of anti-HIV drugs .
|
-
- HY-P4108
-
|
|
Influenza Virus
|
Infection
|
|
TAT-HA2 Fusion Peptide is a peptide-based delivery agent that combines the pH-sensitive HA2 fusion peptide from Influenza and the cell-penetrating peptide TAT from HIV. TAT-HA2 Fusion Peptide is a transactivator of transcription and hemaglutanin for endosomal release. TAT-HA2 Fusion Peptide enhances cellular uptake of macromolecules .
|
-
- HY-P4113
-
|
|
Peptides
|
Neurological Disease
|
|
TAT-NSF700 Fusion Peptide is a potent N-ethyl-maleimide-sensitive factor (NSF) inhibitor. TAT-NSF700 Fusion Peptide can readily permeate the cell membrane and interact with the intracellular organelle directly .
|
-
- HY-P4109A
-
|
NT21MP TFA; V1 peptide TFA
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
vMIP-II (1-21) (NT21MP) TFA is an inhibitor of CXCR4. vMIP-II (1-21) TFA interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) TFA inhibits CXCR4 by competing with 125I-SDF-1R for binding sites (IC50=190 nM) .
|
-
- HY-P10517
-
|
SFT
|
HIV
|
Infection
|
|
Sifuvirtide (SFT) is a potent HIV fusion inhibitor. Sifuvirtide inhibits HIV-1 mediated cell fusion in a dose-dependent manner and is highly potent against infection by primary and laboratory-adapted HIV-1 isolates of multiple genotypes. Sifuvirtide can be used in the research of anti-HIV drugs .
|
-
- HY-P10308
-
|
|
HIV
|
Infection
|
|
[(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) is a selective inhibitor of HIV-1. [(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) inhibits viral infection and cell fusion by blocking the interaction between HIV-1 and CD4 molecules. [(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) can completely inhibit fusion formation at a concentration of 25 μM .
|
-
- HY-P4110
-
|
|
iGluR
|
Metabolic Disease
Inflammation/Immunology
|
|
TAT-NSF222 Fusion Peptide is a fusion polypeptide with two domains, a TAT domain, which enters cells through macropinocytosis, and an NSF domain that inhibits N-ethylmaleimide-sensitive factor (NSF). TAT-NSF222 Fusion Peptide is an exocytosis inhibitor .
|
-
- HY-P10651
-
|
|
Bacterial
|
Infection
|
|
Lifeact peptide is a fusion structure of BP100 bound to actin. BP100 (KKLFKKILKYL-amide) is an antimicrobial peptide against plant pathogens that acts as a fast and effective cell penetrant to transport fluorescent test cargo into the cytoplasm of plant cell walls .
|
-
- HY-P5497
-
|
|
HIV
|
Others
|
|
C34 peptide is a biological active peptide. (This C34 peptide, also known as HR2, belongs to the helical region of gp41 of HIV, C-terminal heptad repeat 2 (HR2) defined as C helix or C peptide. It is known that HIV-1 enters cells by membrane fusion, C34 gp41 peptide is a potent inhibitors of HIV-1 fusion.)
|
-
- HY-P4109
-
|
NT21MP; V1 peptide
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
vMIP-II (1-21) (NT21MP) is an inhibitor of CXCR4. vMIP-II (1-21) interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) inhibits CXCR4 by competing with 125I-SDF-1R for binding sites (IC50=190 nM) .
|
-
- HY-P0175A
-
|
740YPDGFR TFA; PDGFR 740Y-P TFA
|
PI3K
Autophagy
|
Cancer
|
|
740 Y-P TFA is a potent and cell-permeable PI3K activator. 740 Y-P TFA readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
|
-
- HY-P1566
-
|
|
HIV
|
Infection
|
|
MPG, HIV related is 27-aa peptide, derived from both the nuclear localisation sequence of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41 and is a potent delivery agent for the generalised delivery of nucleic acids and of oligonucleotides into cultured cells.
|
-
- HY-P5307
-
|
INF7-A5K-TAT
|
Biochemical Assay Reagents
|
Others
|
|
Peptide A5K (INF7-A5K-TAT) is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .
|
-
- HY-P5307A
-
|
INF7-A5K-TAT acetate
|
Biochemical Assay Reagents
|
Others
|
|
Peptide A5K (INF7-A5K-TAT) acetate is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K acetate can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K acetate enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .
|
-
- HY-P10804
-
|
|
SARS-CoV
|
Infection
|
|
PIH is an antiviral peptide that effectively inhibits the HR1/HR2-mediated membrane fusion between MERS-CoV and host cells, with an IC50 of 1.171 μM. By forming a complex with gold nanorods (AuNRs), the antiviral efficacy of PIH can be further enhanced by 10-fold .
|
-
- HY-P0175
-
|
740YPDGFR; PDGFR 740Y-P
|
PI3K
Autophagy
|
Cancer
|
|
740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
|
-
- HY-P5119
-
|
|
Peptides
|
Neurological Disease
|
|
Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 190-208 (HY-P5118), as Tat-peptide 190-208 increases axon growth and increases the number of neurites per neuron .
|
-
- HY-P5119A
-
|
|
Peptides
|
Neurological Disease
|
|
Tat-peptide 168-189 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 168-189 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 168-189 is the negtive control of Tat-peptide 168-189 TFA (HY-P5118A), as Tat-peptide 168-189 TFA increases axon growth and increases the number of neurites per neuron .
|
-
- HY-P5118
-
|
|
Peptides
|
Neurological Disease
|
|
Tat-peptide 190-208 is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 190-208 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 190-208 increases axon growth and increases the number of neurites per neuron. Tat-peptide 190-208 likely exhibits an axon intrinsic mechanism. Tat-peptide 190-208 can be used for ischemic protection during endovascular repair for intracranial aneurysms .
|
-
- HY-P5320
-
|
|
Apoptosis
|
Others
|
|
TAT-BH4 (Bcl-xL) localized mainly at the mitochondria, prevents apoptotic cell death. TAT-BH4 (Bcl-xL) is a fusion peptide that combines the N-terminal cysteine conjugated protein transduction domain of HIV TAT protein (amino acids 49 to 57) with the Bcl-xL BH4 peptide. TAT-BH4 can be used for research of diseases caused by accelerated apoptosis .
|
-
- HY-P5320A
-
|
|
Apoptosis
|
Others
|
|
TAT-BH4 (Bcl-xL) TFA is localized mainly at the mitochondria, prevents apoptotic cell death. TAT-BH4 (Bcl-xL) is a fusion peptide that combines the N-terminal cysteine conjugated protein transduction domain of HIV TAT protein (amino acids 49 to 57) with the Bcl-xL BH4 peptide. TAT-BH4 TFA can be used for research of diseases caused by accelerated apoptosis .
|
-
- HY-P5118A
-
|
|
Peptides
|
Neurological Disease
|
|
Tat-peptide 190-208 TFA is a cell-permeable and Tat-labeled fusion peptide, corresponding to residues 190-208 of rat G3BP1. Tat sequence from HIV, is placed at the least conserved end of the sequence, for cell permeability. Tat-peptide 190-208 TFA increases axon growth and increases the number of neurites per neuron. Tat-peptide 190-208 TFA likely exhibits an axon intrinsic mechanism. Tat-peptide 190-208 TFA can be used for ischemic protection during endovascular repair for intracranial aneurysms .
|
-
- HY-P5350
-
|
|
Peptides
|
Others
|
|
FN-A208 is a biological active peptide. (This peptide is a fusion of A208, derived from murine laminin a1, and the active site of fibronectin (GRGDS), with a glycine spacer. This peptide forms amyloid-like fibrils and promotes formation of actin stress fibers that mediate fibroblast cell attachment, offering it potential as a bioadhesive for tissue regeneration and engineering. FN-A208 interacts with IKVAV receptors and integrins. Its activity is disrupted by the presence of EDTA.)
|
-
- HY-P10993
-
|
|
Bcl-2 Family
|
Cancer
|
|
CT20p is an anticancer peptide based on the C hydrophobic terminus of Bax. CT20p has a unique cytotoxic effect independent of full-length Bax, and can act on mitochondria, leading to fusion-like aggregation and mitochondrial membrane hyperpolarization. CT20p can reduce α5β1 integrin levels and inhibit F-actin polymerization, thereby destroying the cytoskeleton and preventing cell attachment. CT20p can be used in the study of breast cancer .
|
-
- HY-P5395
-
|
|
HIV
|
Others
|
|
TAT-GluR23A Fusion Peptide is a biological active peptide. (This is the GluR23A sequence, a control inactive peptide used as a mutant counterpart to glutamate receptor endocytosis inhibitor (GluR23Y), connected to an 11 amino acid cell permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). GluR23A is derived from GluR23Y amino acids 869 to 877, with Ala substituted for Tyr, and thus lacking essential phosphorylation sites.Control peptide of HY-P2259)
|
-
- HY-P10976
-
|
|
SARS-CoV
|
Infection
|
|
Spike Glycoprotein (1147-1162) is a linear and broadly neutralizing peptide in the S2 protein of SARS-CoV-2. Spike Glycoprotein (1147-1162) is conserved across SARS-CoV, BatCoV RaTG13, SARS-CoV-2, and SARS-CoV-2 variants. Spike Glycoprotein (1147-1162)-targeting mAbs can neutralize both SARS-CoV-2 and SARS-CoV by preventing fusion between the virus and cell membrane. Spike Glycoprotein (1147-1162) can be used for universal vaccines against SARS-CoV-2 mutants research .
|
-
- HY-P2200
-
|
BMY-29304
|
HIV
Antibiotic
|
Infection
Inflammation/Immunology
|
|
Siamycin I (BMY-29304), a 21-residue tricyclic peptide, is a secondary metabolite in actinomycetes. Siamycin I is a HIV fusion inhibitor with ED50s of 0.05 to 5.7 μM for acute HIV type 1 (HIV-1) and HIV-2 infections. Siamycin I inhibits the gelatinase and gelatinase biosynthesis-activating pheromone (GBAP) signaling via the FsrC-FsrA two-component regulatory system in a noncompetitive manner. Siamycin I suppresses the expression of both fsrBDC and gelE-sprE transcripts. Siamycin I, a lasso peptide, interacts with lipid II and inhibits cell wall biosynthesis. Siamycin I, an antibiotic, has the potential for enterococcal infections research .
|
-
- HY-K3016
-
|
|
|
MCE HAT Supplement (50×) can be added to cell culture medium as a selection agent for post-fusion selection of HGPRT-myeloma hybridoma cells used for antibody production.
|
-
- HY-K0231
-
|
|
|
MCE Anti-c-Myc Affinity Gel can be used for the detection and purification of c-Myc fusion expressed proteins, and immunoprecipitation (IP) experiments to detect the expression of recombinant proteins in target cells.
|
-
- HY-K0232
-
|
|
|
MCE Anti-HA Affinity Gel can be employed for the detection and purification of HA fusion expressed proteins, and can also be used in immunoprecipitation (IP) experiments to detect the expression of recombinant proteins in target cells.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99035
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Naptumomab is a fusion protein of a tumor-targeting superantigen (TTS). Naptumomab stimulates the immune system to recognize and kill tumor cells and can be used in the study of refractory solid tumors such as renal cell carcinoma .
|
-
- HY-P99446
-
|
TACI-Ig; TACI-Fc 5
|
TNF Receptor
|
Inflammation/Immunology
|
|
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .
|
-
- HY-P99667
-
|
OMP-54F28; FZD8-Fc
|
Wnt
|
Cancer
|
|
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
|
-
- HY-P99420
-
|
ALPN-101
|
CD28
|
Inflammation/Immunology
|
|
Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities .
|
-
- HY-P990706
-
|
ALPN-303
|
TNF Receptor
|
Inflammation/Immunology
|
|
Povetacicept (ALPN-303), an Fc fusion protein of an engineered TACI domain, is a dual APRIL/BAFF antagonist. Povetacicept modulates B lymphocytes and pathogenic autoantibodies for the study of Lupus and other B cell-related autoimmune diseases .
|
-
- HY-P99480
-
|
M7824; MSB0011359C
|
TGF-β Receptor
|
Cancer
|
|
Bintrafusp alfa (M 7824) is a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII fused to a human IgG1 mAb blocking programmed cell death ligand. Bintrafusp alfa can be used for the research of cancer .
|
-
- HY-P991344
-
|
|
PD-1/PD-L1
|
Cancer
|
|
AMP-224 is a fusion protein targeting PD-L2. AMP-224 specifically binds to PD-1 T cells (chronically stimulated/exhausted T cells). AMP-224 can be used in Colorectal cancer and Solid tumours research .
|
-
- HY-P990708
-
|
MDNA55; NBI-3001; PRX-321
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Bizaxofusp (MDNA55) is a fusion protein formed by the linkage of IL-4 and a truncated Pseudomonas exotoxin. Bizaxofusp can bind to IL-4 receptors on the surface of tumor cells and be internalized, and its exotoxin moiety can inhibit protein synthesis and induce tumor cell apoptosis. Bizaxofusp can be used in the study of cancer .
|
-
- HY-P991214
-
|
EMD 273066; huKS-IL2
|
Interleukin Related
|
Cancer
|
|
Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine fusion agent targeting the epithelial cell adhesion molecule (EpCAM). Tucotuzumab celmoleukin binds to EpCAM and delivers IL-2 to the tumor microenvironment, which can activate cytotoxic effector cells, such as CD8+ T cells and natural killer (NK) cells. Tucotuzumab celmoleukin is promising for research of EpCAM-positive cancers, such as colorectal cancer and prostate cancer .
|
-
- HY-P991087
-
|
|
FAP
|
Cancer
|
|
RO7122290 is a bispecific fusion protein carrying a split trimeric 4-1BB (CD137) ligand and a fibroblast activation protein α (FAP) binding site. O7122290 is a FAP-α-targeted 4-1BB agonist that costimulates T cells for improved tumor cell killing in FAP-expressing tumors .
|
-
- HY-P99752
-
|
ALKS 4230; RDB-1450
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer .
|
-
- HY-P99339
-
|
IMCgp100
|
Interleukin Related
TNF Receptor
|
Cancer
|
|
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .
|
-
- HY-108847
-
Etanercept
Maximum Cited Publications
9 Publications Verification
|
TNF Receptor
Bacterial
|
Inflammation/Immunology
Cancer
|
|
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .
|
-
- HY-108829
-
|
CTLA4lg; BMS-188667
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
|
-
- HY-108829A
-
|
CTLA4lg (powder); BMS-188667 (powder)
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
|
-
- HY-P99879
-
|
Benegrastim; Bineuta; F 627
|
STAT
|
Inflammation/Immunology
|
|
Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2)-Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells .
|
-
- HY-P99687
-
|
AMG 256
|
PD-1/PD-L1
|
Cancer
|
|
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research .Latikafusp may lead to the development of immunogenicity-mediated responses .
|
-
- HY-P99759
-
|
IL-15N72D
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Nogapendekin alfa (his tag), a soluble protein subunit of a human interleukin (IL)-15 variant, is a superagonist of IL-15. Nogapendekin alfa (his tag) promotes the proliferation and viability of immune cells. Nogapendekin alfa (his tag) combines with Inbakicept (HY-P99661) at a ratio of 2:1, to form N-803 (Nogapendekin alfa inbakicept), an IL-15 cytokine antibody fusion protein. N-803 reduces tumor burden by activation of NK cells and CD8 + T cells .
|
-
- HY-P990017
-
|
CD19-4-1BBL; RO7227166; RG6076
|
CD19
|
Cancer
|
|
Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells .
|
-
- HY-P99844
-
|
ALPN-202; CD80 vIgD-Fc
|
CTLA-4
|
Cancer
|
|
Davoceticept (ALPN-202; CD80 vIgD-Fc) is a variant CD80 vIgD-Fc fusion protein targeting CTLA-4 and PD-L1. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .
|
-
- HY-P99568
-
|
RC18
|
TNF Receptor
|
Inflammation/Immunology
|
|
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease . The component ratio of this product is Active ingredient : Excipients = 1: 0.5-1: 0.8.
|
-
- HY-P99459
-
|
BG 9924; TT-47
|
TNF Receptor
|
Inflammation/Immunology
|
|
Baminercept (BG 9924) is an anti-lymphotoxin β receptor (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA) .
|
-
- HY-P99803
-
|
VAL-1221
|
Glycosidase
|
Others
|
|
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
|
-
- HY-P99661
-
|
|
Interleukin Related
|
Cancer
|
|
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .
|
-
- HY-P991234
-
|
|
EGFR
p38 MAPK
PI3K
Akt
|
Cancer
|
|
COVA208 is a bispecific FynomAb (a fusion protein of an antibody and a Fyn SH3-derived binding protein) that targets HER2. COVA208 induces the degradation of HER2, reduces the levels of HER2, HER3, and EGFR, thereby effectively blocking the downstream signaling pathways of HER2, including the HER3-PI3K-AKT and MAPK pathways, and simultaneously inducing apoptosis of tumor cells. COVA208 is promising for research of cancers, such as HER2-positive breast cancer, gastric cancer, and colorectal cancer .
|
-
- HY-P991524
-
|
|
EGFR
|
Cancer
|
|
MM-111 is a bispecific antibody fusion protein targeting the ErbB2/ErbB3 oncogenic unit. MM-111 blocks activation of the PI3K pro-survival pathway. MM-111 binds to the ErbB2 receptor, which localizes the bispecific molecule to ErbB2 over-expressing tumor cells and promotes binding of the anti-ErbB3 arm to the ErbB3 receptor. MM-111 binding to ErbB3 results in inhibition of ErbB3 signaling by blocking the binding of the ErbB3 physiological ligand heregulin. MM-111 can be used for the study of ErbB2 over-expressing breast tumors .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Compare |
Product Name |
Species |
Source |
Compare Products
|
| Products |
|
| Cat. No. |
|
| Species |
|
| Source |
|
| Tag |
|
| Accession |
|
| Gene ID |
|
| Molecular Weight |
|
| Purity |
|
| Endotoxin Level |
|
| Biological Activity |
|
| Appearance |
|
| Formulation |
|
| Storage & Stability |
|
| Shipping |
|
| Free Sample |
Yes
No
|
| Size |
* This product has been "discontinued".
Optimized version of product available:
|
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-14904AS
-
|
|
|
Umifenovir-d6 (hydrochloride) is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells . Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .
|
-
| Cat. No. |
Compare |
Product Name |
Application |
Reactivity |
Compare Products
|
| Products |
|
| Cat. No. |
|
| Host |
|
| Reactivity |
|
| Application |
|
Dilution
Ratio |
|
| Molecular Weight |
|
| Conjugation |
|
| Clonality |
|
| Immunogen |
|
| Appearance |
|
| Isotype |
|
| Gene ID |
|
| SwissProt ID |
|
| Purity |
|
| Formulation |
|
| Free Sample |
Yes
No
|
| Size |
* This product has been "discontinued".
Optimized version of product available:
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-159147
-
|
|
|
Azide
|
|
SIAIS039 is an orally active c-ros oncogene 1 (ROS1)-specific PROTAC with DC50s of 154.46 nM, 126.47 nM, 143.69 nM for HCC78 cells, Ba/F3 expressing the CD74-ROS1 fusion and Ba/F3 expressing the SDC4-ROS1 fusion, respectively. SIAIS039 suppresses cell proliferation, induces cell cycle arrest and apoptosis, and inhibits clonogenicity against ROS1-positive cells. SIAIS039 demonstrates anti-tumour effects against ROS1-driven tumor growth vivo. SIAIS039 is composed of the ALK inhibitor Brigatinib (HY-12857), a linker EM-12 (HY-138793), and a VHL ligand E3 ubiquitin ligase 1-Butyne (Red: Brigatinib; Blue: VHL ligand; Black: linker) .
|
-
- HY-148202
-
|
|
|
Alkynes
|
|
Influenza antiviral conjugate-1 (INT-2) is a HIV inhibitor, shows potent cell fusion inhibition . Influenza antiviral conjugate-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-W250118
-
|
|
|
Phospholipids
|
|
Phosphatidylethanolamine is an orally active phospholipid widely present in organisms. Phosphatidylethanolamine participates in the formation of autophagosome membrane as a lipid anchor of autophagy-related protein Atg8/LC3. Phosphatidylethanolamine enhances Autophagic flux, promotes cell differentiation, regulates lipid droplet fusion, delays aging, and also affects lipid metabolism and membrane integrity .
|
-
- HY-153083
-
|
|
|
mRNA
|
|
COVID-19 Spike Protein mRNA will express COVID-19 spike protein, and suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 spike protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 spike protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 spike protein is an important site of action for host neutralizing antibodies and a key target for vaccine design .
|
-
- HY-W127378
-
|
1,2-Dioleoyl-3-trimethylammonium-propane methylsulfate
|
|
Cationic Lipids
|
|
DOTAP methylsulfat is a cationic lipid reagent, a cationic derivative of trimethylammonium, linked to two 18-carbon fatty acid tails, each with a single olefin group. DOTAP methylsulfat can self-assemble with negatively charged ions (such as DNA) to form complexes, which can be adsorbed to the cell membrane surface and enter the cell by electrostatic interaction and endocytosis, respectively. DOTAP methylsulfat promotes endosomal membrane fusion with its own hydrophobic domain, releases DNA into the cytoplasm, and exerts gene delivery function. DOTAP methylsulfat can be widely used in research fields such as gene therapy, cell transfection, and non-viral vector design[1][2].
|
-
- HY-145795
-
|
|
|
Cationic Lipids
|
|
OF-02 is an ionizable lipid for mRNA delivery and a key component of lipid nanoparticles (LNPs). OF-02 is protonated in the acidic endosomal environment to promote endosomal escape of mRNA and efficiently induce protein expression in target cells. OF-02 relies on the pH-responsive membrane fusion properties to form a complex with mRNA and destroy the endosomal membrane structure to achieve mRNA release in the cytoplasm. OF-02 is mainly used in the development of mRNA vaccines, gene editing, and protein replacement therapy[1][2][3].
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![[(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92)](http://file.medchemexpress.eu/product_pic/hy-p10308.gif)
